We are currently researching new ways to reduce cardiovascular risk. See below for select trials.
Weekly ONe-Day watER-only Fasting InterventionaL (WONDERFUL) trial for Low-Density Lipoprotein Cholesterol Reduction
The goal of this study is to determine how effective repeated fasting over 26 weeks (6 months) helps to improve risk parameters that are surrogate endpoints for cardiovascular diseases, metabolic dysregulation, and cognitive impairments.
Subjects will be randomized 1:1 to water-only fasting or to their ad libitum usual diet. Randomization will be performed within strata based on fasting history (≤180
hours or 181-720 hours of total fasting for >12 consecutive hours per episode in the previous two years). Subjects will be assessed at 4, 13 and 26 weeks following randomization.
Target-D is a randomized clinical trial evaluating whether achieving an ideal vitamin D level through personalized management of vitamin D supplementation will result in
the reduction of cardiovascular-related outcomes.
Patients enrolled in the study will be followed prospectively for the occurrence of adverse cardiovascular-related outcomes. The study
is anticipated to last for approximately three to four years.
LACE (INSPIRE Sub-Study)
Using the INSPIRE registry, we will identify patients undergoing coronary angiography with a history
of myocardial infarction, percutaneous coronary intervention (PCI), or coronary artery bypass grafting, and increased Lipoprotein(a), or Lp(a), levels. Then, we will look for associations with increased risk of recurrent major cardiovascular events within three years.
In patients who have an echocardiogram, we will look for an association between increased Lp(a) and the
presence of aortic stenosis, as well as the severity and progression of the aortic stenosis.